{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=LAMA&page=2", "query": { "intervention": "LAMA", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=LAMA&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-04T04:07:39.051Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06040086", "title": "Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary Disease (COPD)" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Tozorakimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "40 Years to 130 Years" }, "enrollment_count": 1454, "start_date": "2023-09-22", "completion_date": "2026-05-22", "has_results": false, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-09-04T04:07:39.051Z", "location_count": 57, "location_summary": "Birmingham, Alabama • Decatur, Alabama • Sheffield, Alabama + 51 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Decatur", "state": "Alabama" }, { "city": "Sheffield", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06040086" }, { "nct_id": "NCT03219866", "title": "Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "COPD", "COPD Exacerbation" ], "interventions": [ { "name": "Nebulizers", "type": "DEVICE" }, { "name": "Dry Powder Inhaler", "type": "DEVICE" }, { "name": "Brovana", "type": "DRUG" }, { "name": "Pulmicort", "type": "DRUG" }, { "name": "Atrovent", "type": "DRUG" }, { "name": "Advair Diskus", "type": "DRUG" }, { "name": "Spiriva HandiHaler", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 40, "start_date": "2017-10-03", "completion_date": "2020-04-01", "has_results": true, "last_update_posted_date": "2021-06-22", "last_synced_at": "2026-09-04T04:07:39.051Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03219866" }, { "nct_id": "NCT04718389", "title": "A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "GSK3511294 (Depemokimab)", "type": "BIOLOGICAL" }, { "name": "Mepolizumab", "type": "BIOLOGICAL" }, { "name": "Benralizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "Standard of care (SoC)", "type": "DRUG" }, { "name": "Pre-filled Syringes (PFS)", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DEVICE" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 1717, "start_date": "2021-01-26", "completion_date": "2025-09-14", "has_results": true, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-09-04T04:07:39.051Z", "location_count": 119, "location_summary": "Birmingham, Alabama • Scottsboro, Alabama • Litchfield Park, Arizona + 94 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsboro", "state": "Alabama" }, { "city": "Litchfield Park", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04718389" }, { "nct_id": "NCT04072887", "title": "Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "QBW251", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "COPD maintenance background therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 974, "start_date": "2019-09-12", "completion_date": "2022-02-01", "has_results": true, "last_update_posted_date": "2023-04-28", "last_synced_at": "2026-09-04T04:07:39.051Z", "location_count": 25, "location_summary": "Andalusia, Alabama • Los Angeles, California • Westminster, California + 22 more", "locations": [ { "city": "Andalusia", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Westminster", "state": "California" }, { "city": "Ormond Beach", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04072887" }, { "nct_id": "NCT01691547", "title": "A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "UMEC /VI", "type": "DRUG" }, { "name": "UMEC", "type": "DRUG" }, { "name": "VI", "type": "DRUG" }, { "name": "FF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 44, "start_date": "2012-12-17", "completion_date": "2013-03-08", "has_results": false, "last_update_posted_date": "2017-07-26", "last_synced_at": "2026-09-04T04:07:39.051Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01691547" }, { "nct_id": "NCT01709864", "title": "NVA237 Versus Placebo 12-week Efficacy Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "NVA237", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 440, "start_date": "2012-11", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2015-03-04", "last_synced_at": "2026-09-04T04:07:39.051Z", "location_count": 54, "location_summary": "Homewood, Alabama • Jasper, Alabama • *See Various Dept.'s*, Arizona + 43 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Jasper", "state": "Alabama" }, { "city": "*See Various Dept.'s*", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01709864" }, { "nct_id": "NCT04053634", "title": "Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "Benralizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "40 Years to 85 Years" }, "enrollment_count": 689, "start_date": "2019-08-26", "completion_date": "2025-07-28", "has_results": false, "last_update_posted_date": "2025-08-19", "last_synced_at": "2026-09-04T04:07:39.051Z", "location_count": 84, "location_summary": "Surprise, Arizona • Little Rock, Arkansas • Los Angeles, California + 77 more", "locations": [ { "city": "Surprise", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04053634" }, { "nct_id": "NCT02537691", "title": "Longitudinal Cohort Study in Participants With Severe Asthma to Assess Biomarkers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "FP", "type": "DRUG" }, { "name": "LABA", "type": "DRUG" }, { "name": "LTRA", "type": "DRUG" }, { "name": "LAMA", "type": "DRUG" }, { "name": "Theophylline", "type": "DRUG" }, { "name": "Oral Corticosteroids", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 483, "start_date": "2015-08-28", "completion_date": "2017-07-10", "has_results": false, "last_update_posted_date": "2019-04-09", "last_synced_at": "2026-09-04T04:07:39.051Z", "location_count": 29, "location_summary": "Birmingham, Alabama • Mission Viejo, California • Sacramento, California + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mission Viejo", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02537691" }, { "nct_id": "NCT04184297", "title": "Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to Triple Therapy", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Tiotropium and Olodaterol (Tio+Olo)", "type": "DRUG" }, { "name": "Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 27190, "start_date": "2019-11-01", "completion_date": "2019-11-04", "has_results": true, "last_update_posted_date": "2021-11-15", "last_synced_at": "2026-09-04T04:07:39.051Z", "location_count": 1, "location_summary": "Andover, Massachusetts", "locations": [ { "city": "Andover", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04184297" }, { "nct_id": "NCT02948959", "title": "Evaluation of Dupilumab in Children With Uncontrolled Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Dupilumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Asthma Controller Therapies", "type": "DRUG" }, { "name": "Asthma Reliever Therapies", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "6 Years to 11 Years" }, "enrollment_count": 408, "start_date": "2017-04-21", "completion_date": "2020-08-26", "has_results": true, "last_update_posted_date": "2022-03-28", "last_synced_at": "2026-09-04T04:07:39.051Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Rolling Hills Estates", "state": "California" }, { "city": "Owensboro", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT02948959" } ] }